Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Jul 30, 2026
UBS (UBS) Reports Strong Q2 2026 Results with +17% Profit Growth

UBS (UBS) Reports Strong Q2 2026 Results with +17% Profit Growth

Key Takeaways

  • Net profit reached $2.8 billion in the second quarter, comfortably exceeding the analyst consensus estimate of $2.39 billion and rising 17% year over year.
  • Global Wealth Management attracted $36 billion in net new assets, significantly outpacing analyst forecasts of roughly $21 billion, underscoring strong client confidence in the combined UBS–Credit Suisse franchise.
  • The Investment Bank posted a record second-quarter performance, with pre-tax profit more than doubling to $1.2 billion, driven by surging equities trading and capital markets activity.
  • A new $3 billion share buyback program was announced, with at least $1 billion expected to be repurchased over the next three months, following the completion of the prior $3 billion program in July.
  • Cumulative cost savings from the Credit Suisse integration reached $12.6 billion, representing more than 90% of the $13.5 billion target, with the integration on track for substantial completion by year-end 2026.
  • The internal workforce fell below 100,000 for the first time since the Credit Suisse acquisition, reflecting disciplined headcount management as legacy IT systems are decommissioned.

Earnings Context and Why It Matters

UBS Group AG's second-quarter 2026 results mark a pivotal moment in the bank's post-acquisition journey. Nearly three years after the government-brokered rescue of Credit Suisse, this earnings release provides the clearest evidence yet that the merger thesis is delivering on its promises. With integration milestones accelerating, cost savings materializing ahead of schedule, and client flows remaining robust, the quarter offered investors a tangible progress report on one of the most complex banking integrations in modern history. The results also arrive at a critical juncture for Swiss banking regulation, as Parliament deliberates on capital requirements that could materially shape UBS's future capital return capacity. For the market, this earnings report serves as a dual test: sustaining organic business momentum while navigating unresolved regulatory headwinds.

The Reported Numbers

UBS reported net profit attributable to shareholders of $2.8 billion for the second quarter of 2026, exceeding the company-provided analyst consensus of $2.39 billion. Earnings per share (EPS) came in at $0.87, while group revenue rose 16% year over year to $13.3 billion. Underlying pre-tax profit surged 45% to $3.9 billion, and the underlying return on CET1 capital reached 16.4%.

Global Wealth Management generated $2 billion in pre-tax profit, up 38% from the prior-year quarter, supported by $36 billion in net new assets. The Investment Bank delivered exceptional results with pre-tax profit of $1.2 billion — more than double the year-ago figure — on revenue of $3.7 billion, a 31% increase. Asset Management posted pre-tax profit of $237 million, up 9%, with assets under management surpassing $2.2 trillion. The Personal and Corporate Banking division contributed CHF 676 million in pre-tax profit, a 21% increase, while group credit loss expenses remained contained at CHF 61 million.

The bank's CET1 capital ratio stood at 14.4% at quarter-end, and the group's cost-to-income ratio improved to 70% on an underlying basis. Cumulative gross cost savings from the Credit Suisse integration reached $12.6 billion, placing UBS well within reach of its $13.5 billion target. Total invested assets across the group climbed to a record $7.3 trillion. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Market Reaction and Investor Sentiment

UBS shares rose approximately 1% to 3% in early trading following the results, with the stock trading near the upper end of its 52-week range. The positive but measured market reaction reflected a balance between strong underlying performance and lingering cautiousness around the pace of future capital returns. While net profit comfortably beat consensus, headline EPS of $0.87 fell slightly short of some third-party estimates, and revenue was broadly in line with or marginally below certain forecasts. Analysts at Vontobel noted that the earnings beat was concentrated in investment banking trading, with the other three operating divisions exceeding consensus by a narrower margin. Nonetheless, the $36 billion wealth management inflow — nearly double some analyst forecasts — and the new $3 billion buyback commitment were widely viewed as signals of confidence from management. Sentiment heading into the quarter had been cautiously optimistic, and the results largely validated that positioning, though unresolved Swiss capital regulation remains a key overhang for longer-term institutional investors.

Forward Outlook and Key Factors to Monitor

Looking ahead, UBS enters the second half of 2026 with several tailwinds and a few unresolved challenges. The most immediate catalyst for investors is the progress of Swiss parliamentary deliberations on capital requirements for systemically important banks, with the next key committee session scheduled for mid-August. The proposed framework could require UBS to hold an additional $20 billion or more in CET1 capital against its foreign subsidiaries — a requirement CEO Sergio Ermotti has publicly described as excessive and competitively damaging. Any softening of that stance by lawmakers would likely be received positively by the market and could unlock a faster pace of share buybacks beyond the newly announced $3 billion program.

On the operational side, the Credit Suisse integration is approaching its final chapter. With over 90% of legacy IT applications no longer in use and roughly 70% already fully decommissioned, UBS is targeting substantial completion by the end of 2026. Achieving this milestone would remove one of the largest execution risks that has hung over the stock since the 2023 acquisition.

Investors should also monitor wealth management flows in the Americas, where elevated advisor attrition has created pockets of client outflow. The division posted $1 billion in net inflows during Q2 even after a $10 billion seasonal tax-related outflow, offering early signs of stabilization. Meanwhile, management cautioned that geopolitical uncertainty, volatile energy prices, and potential shifts in inflation and interest rate expectations could create temporary headwinds in the third quarter, even as underlying client activity remains healthy and supportive of continued revenue growth. I reviewed recent patterns with Tickeron’s AI Real Time Patterns to gauge potential near-term moves.

Using Tickeron’s AI Screener in My Research

When evaluating financial names like this one, I often turn to Tickeron’s AI Screener to filter peers by metrics such as revenue growth, capital ratios, and AI signals. It helps me quickly spot how UBS stacks up against the broader sector without spending hours on manual screens.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: UBS

UBS in +1.92% Uptrend, growing for three consecutive days on July 27, 2026

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where UBS advanced for three days, in of 345 cases, the price rose further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

The Aroon Indicator entered an Uptrend today. In of 322 cases where UBS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for UBS moved out of overbought territory on July 16, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 45 similar instances where the indicator moved out of overbought territory. In of the 45 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Momentum Indicator moved below the 0 level on July 28, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on UBS as a result. In of 76 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for UBS turned negative on July 20, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 41 similar instances when the indicator turned negative. In of the 41 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where UBS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

UBS broke above its upper Bollinger Band on July 14, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 21, placing this stock better than average.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. UBS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.904) is normal, around the industry mean (1.906). UBS's P/E Ratio (32.733) is considerably higher than the industry average of (16.026). Projected Growth (PEG Ratio) (0.937) is also within normal values, averaging (1.640). Dividend Yield (0.021) settles around the average of (0.026) among similar stocks. UBS's P/S Ratio (8.210) is very high in comparison to the industry average of (4.252).

Notable companies

The most notable companies in this group are JPMorgan Chase & Co (NYSE:JPM), Bank of America Corp (NYSE:BAC), HSBC Holdings PLC (NYSE:HSBC), Wells Fargo & Co (NYSE:WFC), Citigroup (NYSE:C), Barclays PLC (NYSE:BCS).

Industry description

Major banks are among the biggest companies in the world, often times with global reach and market capitalizations in the multi-billions. Large banks often have multiple arms spanning different disciplines, from deposits, to investment banking, to wealth management and insurance. The biggest banks often have key competitive advantages over smaller players in the industry in terms of brand recognition, cost of capital, and efficiency. Think J.P. Morgan, Bank of America, Wells Fargo, and Citigroup.

Market Cap

The average market capitalization across the Major Banks Industry is 209.36B. The market cap for tickers in the group ranges from 1.04M to 916.31B. JPM holds the highest valuation in this group at 916.31B. The lowest valued company is BACRP at 1.04M.

High and low price notable news

The average weekly price growth across all stocks in the Major Banks Industry was -2%. For the same Industry, the average monthly price growth was 2%, and the average quarterly price growth was 16%. FRBT experienced the highest price growth at 1%, while BCS experienced the biggest fall at -7%.

Volume

The average weekly volume growth across all stocks in the Major Banks Industry was -8%. For the same stocks of the Industry, the average monthly volume growth was 24% and the average quarterly volume growth was 3%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 67
P/E Growth Rating: 32
Price Growth Rating: 39
SMR Rating: 8
Profit Risk Rating: 21
Seasonality Score: -11 (-100 ... +100)
View a ticker or compare two or three
UBS
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a major bank

Industry MajorBanks

Profile
Details
Industry
Major Banks
Address
Bahnhofstrasse 45
Phone
+41 442341111
Employees
112842
Web
https://www.ubs.com
Interact to see
Advertisement
The Travelers Companies, Inc.(TRV), a major player in the property and casualty insurance market, reported fourth-quarter 2025 results on January 21, 2026, closing out a year marked by underwriting discipline despite volatile weather activity and pricing pressures. The results underscore Travelers’ ability to generate strong profitability while navigating challenges in personal insurance lines and heightened catastrophe risk.
FingerMotion, Inc. (NASDAQ: FNGR) reported fiscal third-quarter 2026 results on January 15, 2026, triggering a sharp selloff as investors reacted to a steep revenue decline and widening losses. Shares fell roughly 32% following the release after the mobile services provider disclosed a 32% year-over-year drop in revenue and a net loss of $1.67 million for the quarter ended November 30, 2025.
CSX (NASDAQ: CSX) reports Q4 2025 earnings after market close on January 22, 2026, with consensus EPS ~$0.42 and revenue ~$3.57 billion. Union Pacific (NYSE: UNP) follows on January 27, with EPS expected near $2.89 and revenue around $6.15 billion. Norfolk Southern (NYSE: NSC) closes the week on January 29, with consensus EPS ~$2.77.
The SPDR S&P Aerospace & Defense ETF (XAR) has surged to a new 52-week high above $281 this week, climbing 21% month-to-date and 20% year-to-date through January 2026. The rally, driven by robust sector momentum and a clean technical breakout, is outpacing broader indices like the S&P 500. XAR’s equal-weighted structure amplifies gains from top aerospace and defense holdings in missiles, aircraft, and space systems, attracting significant trader and institutional attention amid heightened geopolitical tensions.
The iShares U.S. Aerospace & Defense ETF (ITA) continues to attract trader attention, building on a remarkable 47.7% gain in 2025 amid rising defense budgets and heightened global security concerns. The ETF is approaching all-time highs, with top holdings such as GE Aerospace and RTX Corporation driving the rally. Traders are adding positions on dips while monitoring confirmation above key resistance levels near recent peaks, anticipating a potential technical breakout.
Chevron’s upcoming Q4 report highlights its first full quarters integrating Hess, following record Q3 production of 4.1 million barrels of oil equivalent per day (MMboe/d). Comparing CVX with ExxonMobil and Shell provides insight into how each supermajor is navigating a volatile oil market with prices hovering below $60 per barrel.
SoFi Technologies is set to report Q4 and full-year 2025 earnings on January 30, 2026, closing out a pivotal year for the digital finance platform. With its fiscal year ending December 31, the report follows a strong Q3 that featured record net revenue of $962 million and member growth to 12.6 million, a 35% year-over-year increase.
ASML reported Q4 2025 net sales of $9.7 billion, gross margin of 52.2%, net income of $2.8 billion, and record net bookings of $13.2 billion, including $7.4 billion in EUV orders.
IDEXX Laboratories (IDXX) reports Q4 2025 earnings on February 2, 2026, with analysts expecting continued strength in recurring revenue from companion animal diagnostics. Danaher (DHR) reports on January 28, while Thermo Fisher Scientific (TMO) follows in early February, with both facing low-single-digit core growth expectations across life sciences and diagnostics.
NIO Inc. (NIO) produced its one-millionth vehicle this week at its Hefei facility, closing out a record 2025 delivery total of 326,028 units, up 46.9% year over year. The milestone, announced January 6, reflects accelerating demand for core models such as the ES8 SUV and newer brands ONVO and Firefly.
Faraday Future Intelligent Electric Inc. (FFAI) shares traded near $1.02 this week following announcements of a non-binding $10 million stock purchase term sheet with AIxCrypto (AIxC) and preparations for a Stockholders’ Day on January 7, 2026. Trading volume spiked amid broader EV volatility, highlighting investor attention on FFAI’s pivot toward AI-enhanced mobility and robotics.
BTQ Technologies Corp. (BTQ), formerly BTQQF, launched the Bitcoin Quantum testnet this week—the first quantum-safe Bitcoin fork, 17 years after Bitcoin’s genesis block. The move coincided with inclusion in the $524.5 million VanEck Quantum Computing UCITS ETF, boosting European investor visibility.
VEU targets large- and mid-cap ex-U.S. stocks with ~3,800 holdings. VXUS offers broad all-cap exposure, including ~8,600 stocks across small-, mid-, and large-cap companies.
Apple (AAPL) reports Q1 FY2026 earnings on January 29, with consensus revenue at $138.5B and EPS at $2.67, supported by strong demand for iPhone 17 models, higher average selling prices, and continued Services growth. Microsoft (MSFT) reports Q2 FY2026 on January 28, expecting $80.3B revenue and $3.91 EPS, driven by Azure AI adoption and enterprise cloud expansion, though elevated capex spending (~$35B/quarter) remains under scrutiny.
Visa Inc. (V), the global payments network leader, reports Q1 FY2026 earnings on January 29, 2026, for the period ending December 31, 2025. This marks the start of FY2026 following a strong FY2025, where net revenue reached $40 billion (+11%) and EPS climbed to $11.47 (+14%). Investors are watching closely for insights into consumer spending, cross-border travel recovery, and digital payment adoption.
Novartis (NVS) reports Q4/FY 2025 earnings on February 4, 2026, with consensus calling for ~$1.99 EPS on ~$13.7 billion in revenue. Sanofi (SNY) delivered strong FY 2025 results on January 29, reporting €43.6 billion in sales (+9.9% CER) and 15% business EPS growth.
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
MUFG is expected to report Q3 FY2026 EPS of about $0.30, broadly in line with its recent pattern of earnings beats.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.